iBio, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for IBIO, updated each market day.
IBIO AI Sentiment
AI predicts iBio, Inc. stock is likely to increase over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About iBio, Inc.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Sector
Exchange
Market Cap
$80,384,070
Cap Tier
Employees
23
Headquarters
NEW YORK, NY
Listed Since
Aug. 19, 2008
Website
IBIO Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IBIO Volatility
iBio, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
